Oakley Carmen L, Nigro Matthew A, Vote Brendan J
Tasmanian Eye Institute, Launceston, Tasmania, Australia.
Tasmanian Eye Institute, Launceston, Tasmania, Australia; Launceston Eye Institute, Launceston, Tasmania, Australia.
GMS Ophthalmol Cases. 2015 Sep 10;5:Doc06. doi: 10.3205/oc000028. eCollection 2015.
The Strampelli anterior chamber intraocular lens was created in 1953, and was primarily used to treat myopia and aphakia. Due to the positioning of the lens, it was associated with a number of complications, and was later modified to decrease the rate of significant complications, including endothelial cell loss. This paper describes a 62-year-old man, who has had a Strampelli intraocular lens (IOL) in situ for 52 years, with relatively few complications. The case provides a framework for reflection on the significant advances in the development of IOLs since the Strampelli era. The Strampelli anterior chamber intraocular lens was created in 1953, and was primarily used to treat myopia and aphakia. Due to the positioning of the lens, it was associated with a number of complications, and was later modified to decrease the rate of significant complications, including endothelial cell loss. This paper describes a 62-year-old man, who has had a Strampelli intraocular lens (IOL) in situ for 52 years, with relatively few complications. The case provides a framework for reflection on the significant advances in the development of IOLs since the Strampelli era.
斯特兰佩利前房型人工晶状体于1953年问世,主要用于治疗近视和无晶状体眼。由于晶状体的位置,它与许多并发症相关,后来进行了改良以降低包括内皮细胞损失在内的严重并发症发生率。本文描述了一名62岁男性,其眼内植入斯特兰佩利人工晶状体(IOL)达52年,并发症相对较少。该病例为反思自斯特兰佩利时代以来人工晶状体发展的重大进展提供了一个框架。斯特兰佩利前房型人工晶状体于1953年问世,主要用于治疗近视和无晶状体眼。由于晶状体的位置,它与许多并发症相关,后来进行了改良以降低包括内皮细胞损失在内的严重并发症发生率。本文描述了一名62岁男性,其眼内植入斯特兰佩利人工晶状体(IOL)达52年,并发症相对较少。该病例为反思自斯特兰佩利时代以来人工晶状体发展的重大进展提供了一个框架。